Rock Springs Capital Management
Latest statistics and disclosures from Rock Springs Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BPMC, IMCR, NBIX, EVH, ISRG, and represent 19.96% of Rock Springs Capital Management's stock portfolio.
- Added to shares of these 10 stocks: LLY (+$80M), CLDX (+$37M), OSCR (+$31M), SGRY (+$29M), MDGL (+$24M), VKTX (+$21M), ACHC (+$21M), NVO (+$19M), INSP (+$19M), GPCR (+$18M).
- Started 19 new stock positions in PHVS, SGRY, VKTX, BHVN, CRL, KYTX, CGON, AUTL, NMRA, GPCR. JSPR, NVO, DYN, CRNX, LLY, VERA, NUVL, ELVN, OSCR.
- Reduced shares in these 10 stocks: HUM (-$100M), Karuna Therapeutics Ord (-$86M), Seagen (-$85M), CERE (-$84M), Mirati Therapeutics (-$49M), IMCR (-$37M), Horizon Therapeutics (-$30M), Abcam Plc Ads (-$29M), AGIO (-$28M), .
- Sold out of its positions in Abcam Plc Ads, SLRN, SYRE, AMGN, BCEL, AURA, CRVO, CYTK, DSGN, FATE.
- Rock Springs Capital Management was a net seller of stock by $-198M.
- Rock Springs Capital Management has $3.9B in assets under management (AUM), dropping by 5.51%.
- Central Index Key (CIK): 0001595725
Tip: Access up to 7 years of quarterly data
Positions held by Rock Springs Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv![Download consolidated filings csv](/static/img/csv.png)
![Download consolidated filings xlsx](/static/img/microsoft-excel.png)
Portfolio Holdings for Rock Springs Capital Management
Rock Springs Capital Management holds 113 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Blueprint Medicines (BPMC) | 6.0 | $237M | -6% | 2.5M | 94.86 |
|
Immunocore Hldgs Ads (IMCR) | 3.9 | $154M | -19% | 2.4M | 65.00 |
|
Neurocrine Biosciences (NBIX) | 3.7 | $146M | -14% | 1.1M | 137.92 |
|
Evolent Health Cl A (EVH) | 3.3 | $131M | +3% | 4.0M | 32.79 |
|
Intuitive Surgical Com New (ISRG) | 3.0 | $119M | 299k | 399.09 |
|
|
UnitedHealth (UNH) | 2.9 | $114M | 230k | 494.70 |
|
|
Penumbra (PEN) | 2.9 | $113M | 505k | 223.18 |
|
|
IDEXX Laboratories (IDXX) | 2.5 | $97M | -7% | 179k | 539.93 |
|
Acadia Healthcare (ACHC) | 2.4 | $93M | +29% | 1.2M | 79.22 |
|
Argenx Se Sponsored Adr (ARGX) | 2.3 | $90M | -11% | 229k | 393.72 |
|
Boston Scientific Corporation (BSX) | 2.1 | $84M | +6% | 1.2M | 68.49 |
|
Ultragenyx Pharmaceutical (RARE) | 2.1 | $83M | +20% | 1.8M | 46.69 |
|
Dex (DXCM) | 2.1 | $83M | +2% | 597k | 138.70 |
|
Eli Lilly & Co. (LLY) | 2.0 | $80M | NEW | 103k | 777.96 |
|
Freshpet (FRPT) | 1.9 | $77M | 663k | 115.86 |
|
|
Madrigal Pharmaceuticals (MDGL) | 1.9 | $76M | +45% | 286k | 267.04 |
|
EXACT Sciences Corporation (EXAS) | 1.9 | $73M | +4% | 1.1M | 69.06 |
|
Align Technology (ALGN) | 1.8 | $72M | 220k | 327.92 |
|
|
Rhythm Pharmaceuticals (RYTM) | 1.7 | $66M | -4% | 1.5M | 43.33 |
|
Edwards Lifesciences (EW) | 1.6 | $62M | 647k | 95.56 |
|
|
Kymera Therapeutics (KYMR) | 1.6 | $61M | 1.5M | 40.20 |
|
|
Celldex Therapeutics Com New (CLDX) | 1.5 | $58M | +174% | 1.4M | 41.97 |
|
Phreesia (PHR) | 1.4 | $57M | +33% | 2.4M | 23.93 |
|
Insulet Corporation (PODD) | 1.4 | $55M | -15% | 320k | 171.40 |
|
West Pharmaceutical Services (WST) | 1.4 | $54M | -32% | 137k | 395.71 |
|
Xenon Pharmaceuticals (XENE) | 1.4 | $54M | +6% | 1.3M | 43.05 |
|
Agilon Health (AGL) | 1.4 | $54M | +6% | 8.8M | 6.10 |
|
Merus N V (MRUS) | 1.3 | $52M | +36% | 1.1M | 45.03 |
|
Agios Pharmaceuticals (AGIO) | 1.3 | $52M | -34% | 1.8M | 29.24 |
|
Humana (HUM) | 1.3 | $51M | -66% | 147k | 346.72 |
|
Mirum Pharmaceuticals (MIRM) | 1.2 | $47M | 1.9M | 25.12 |
|
|
Irhythm Technologies (IRTC) | 1.2 | $46M | +11% | 392k | 116.00 |
|
Shockwave Med | 1.1 | $44M | -8% | 135k | 325.63 |
|
Ascendis Pharma A/s Sponsored Adr (ASND) | 1.1 | $44M | -31% | 290k | 151.17 |
|
Sarepta Therapeutics (SRPT) | 1.1 | $42M | -16% | 328k | 129.46 |
|
Brooks Automation (AZTA) | 1.1 | $42M | +45% | 695k | 60.28 |
|
Alnylam Pharmaceuticals Call Option (ALNY) | 1.0 | $41M | 277k | 149.45 |
|
|
Olink Hldg Ab Sponsored Ads (OLK) | 1.0 | $39M | 1.7M | 23.51 |
|
|
Immunovant (IMVT) | 0.9 | $37M | +78% | 1.2M | 32.31 |
|
Accolade (ACCD) | 0.9 | $37M | +21% | 3.5M | 10.48 |
|
Akero Therapeutics (AKRO) | 0.8 | $33M | -8% | 1.3M | 25.26 |
|
Oscar Health Cl A (OSCR) | 0.8 | $31M | NEW | 2.1M | 14.87 |
|
Pacira Pharmaceuticals (PCRX) | 0.8 | $31M | 1.1M | 29.22 |
|
|
Revolution Medicines (RVMD) | 0.8 | $30M | +27% | 924k | 32.23 |
|
Lifestance Health Group (LFST) | 0.7 | $30M | +30% | 4.8M | 6.17 |
|
Surgery Partners (SGRY) | 0.7 | $29M | NEW | 985k | 29.83 |
|
Warby Parker Cl A Com (WRBY) | 0.7 | $28M | +32% | 2.1M | 13.61 |
|
Inozyme Pharma (INZY) | 0.7 | $28M | 3.7M | 7.66 |
|
|
Inspire Med Sys (INSP) | 0.7 | $28M | +193% | 131k | 214.79 |
|
Legend Biotech Corp Sponsored Ads (LEGN) | 0.7 | $28M | +8% | 500k | 56.09 |
|
Mereo Biopharma Group Spon Ads (MREO) | 0.7 | $27M | +6% | 8.1M | 3.30 |
|
Travere Therapeutics (TVTX) | 0.7 | $26M | +89% | 3.4M | 7.71 |
|
Cerevel Therapeutics Hldng I (CERE) | 0.6 | $23M | -78% | 548k | 42.27 |
|
Disc Medicine (IRON) | 0.6 | $23M | 364k | 62.26 |
|
|
Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.6 | $22M | 562k | 38.82 |
|
|
Viking Therapeutics (VKTX) | 0.5 | $21M | NEW | 261k | 82.00 |
|
Dynavax Technologies Corp Com New (DVAX) | 0.5 | $21M | -7% | 1.7M | 12.41 |
|
Zai Lab Adr (ZLAB) | 0.5 | $21M | +4% | 1.3M | 16.02 |
|
Macrogenics (MGNX) | 0.5 | $19M | +10% | 1.3M | 14.72 |
|
Novo-nordisk A S Adr (NVO) | 0.5 | $19M | NEW | 148k | 128.40 |
|
Krystal Biotech (KRYS) | 0.5 | $19M | +14% | 104k | 177.93 |
|
BioCryst Pharmaceuticals (BCRX) | 0.5 | $18M | +37% | 3.5M | 5.08 |
|
Structure Therapeutics Sponsored Ads (GPCR) | 0.4 | $18M | NEW | 413k | 42.86 |
|
Pharvaris N V (PHVS) | 0.4 | $17M | NEW | 753k | 23.11 |
|
Prothena Corp SHS (PRTA) | 0.4 | $16M | 625k | 24.77 |
|
|
Nevro (NVRO) | 0.4 | $15M | -12% | 1.1M | 14.44 |
|
Vera Therapeutics Cl A (VERA) | 0.4 | $15M | NEW | 341k | 43.12 |
|
Mersana Therapeutics (MRSN) | 0.3 | $14M | -10% | 3.0M | 4.48 |
|
Amicus Therapeutics (FOLD) | 0.3 | $14M | +8% | 1.2M | 11.78 |
|
Crinetics Pharmaceuticals In (CRNX) | 0.3 | $14M | NEW | 289k | 46.81 |
|
Charles River Laboratories (CRL) | 0.3 | $13M | NEW | 49k | 270.95 |
|
BioMarin Pharmaceutical (BMRN) | 0.3 | $13M | -43% | 149k | 87.34 |
|
Dyne Therapeutics (DYN) | 0.3 | $13M | NEW | 452k | 28.39 |
|
Jasper Therapeutics Com New (JSPR) | 0.3 | $12M | NEW | 404k | 29.36 |
|
Compass Therapeutics (CMPX) | 0.3 | $11M | 5.5M | 1.98 |
|
|
Edap Tms S A Sponsored Adr (EDAP) | 0.3 | $11M | +8% | 1.5M | 7.35 |
|
Mineralys Therapeutics (MLYS) | 0.3 | $10M | -32% | 793k | 12.91 |
|
Applied Therapeutics (APLT) | 0.3 | $10M | +85% | 1.5M | 6.80 |
|
Nuvalent Inc-a (NUVL) | 0.2 | $9.4M | NEW | 125k | 75.09 |
|
Acumen Pharmaceuticals (ABOS) | 0.2 | $9.3M | -18% | 2.3M | 4.05 |
|
Immatics SHS (IMTX) | 0.2 | $8.9M | -54% | 849k | 10.51 |
|
Neumora Therapeutics (NMRA) | 0.2 | $8.9M | NEW | 646k | 13.75 |
|
Enliven Therapeutics (ELVN) | 0.2 | $7.5M | NEW | 429k | 17.59 |
|
Cg Oncology (CGON) | 0.2 | $7.5M | NEW | 171k | 43.90 |
|
Biohaven (BHVN) | 0.2 | $6.9M | NEW | 127k | 54.69 |
|
Fulcrum Therapeutics (FULC) | 0.2 | $6.9M | 728k | 9.44 |
|
|
Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $6.6M | NEW | 1.0M | 6.38 |
|
Pulmonx Corp (LUNG) | 0.2 | $6.0M | 652k | 9.27 |
|
|
Aurinia Pharmaceuticals (AUPH) | 0.1 | $5.8M | +139% | 1.2M | 5.01 |
|
Essa Pharma Com New (EPIX) | 0.1 | $5.7M | 677k | 8.49 |
|
|
Pliant Therapeutics (PLRX) | 0.1 | $5.7M | -21% | 385k | 14.90 |
|
Beam Therapeutics (BEAM) | 0.1 | $4.9M | +32% | 148k | 33.04 |
|
Vincerx Pharma Com New (VINC) | 0.1 | $4.5M | 892k | 5.06 |
|
|
Kyverna Therapeutics (KYTX) | 0.1 | $4.4M | NEW | 179k | 24.84 |
|
Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $4.2M | +4% | 771k | 5.42 |
|
Gossamer Bio (GOSS) | 0.1 | $3.9M | 3.3M | 1.18 |
|
|
Gossamer Bio Note 5.000% 6/0 (Principal) | 0.1 | $3.8M | 9.6M | 0.40 |
|
|
Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $3.8M | -12% | 2.4M | 1.58 |
|
Aclaris Therapeutics (ACRS) | 0.1 | $3.4M | -30% | 2.8M | 1.24 |
|
Compugen Ord (CGEN) | 0.1 | $3.3M | 1.3M | 2.58 |
|
|
Amylyx Pharmaceuticals (AMLX) | 0.1 | $2.9M | -34% | 1.0M | 2.84 |
|
Travere Therapeutics Note 2.500% 9/1 (Principal) | 0.1 | $2.8M | 3.3M | 0.87 |
|
|
Biomea Fusion (BMEA) | 0.1 | $2.7M | 181k | 14.95 |
|
|
Novavax Com New (NVAX) | 0.1 | $2.6M | -16% | 538k | 4.78 |
|
Leap Therapeutics Com New (LPTX) | 0.1 | $2.4M | -15% | 912k | 2.66 |
|
Spruce Biosciences (SPRB) | 0.1 | $2.1M | -4% | 2.6M | 0.79 |
|
Neurocrine Biosciences Note 2.250% 5/1 (Principal) | 0.0 | $1.8M | 1.0M | 1.81 |
|
|
Vigil Neuroscience (VIGL) | 0.0 | $1.6M | 472k | 3.41 |
|
|
Xilio Therapeutics (XLO) | 0.0 | $1.6M | 1.4M | 1.08 |
|
|
Reneo Pharmaceuticals (RPHM) | 0.0 | $1.2M | -34% | 752k | 1.66 |
|
Nevro Corp Note 2.750% 4/0 (Principal) | 0.0 | $474k | 500k | 0.95 |
|
|
Talphera Com New (TLPH) | 0.0 | $326k | 317k | 1.03 |
|
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $41k | 134k | 0.30 |
|
Past Filings by Rock Springs Capital Management
SEC 13F filings are viewable for Rock Springs Capital Management going back to 2013
- Rock Springs Capital Management 2024 Q1 filed May 15, 2024
- Rock Springs Capital Management 2023 Q3 filed Nov. 14, 2023
- Rock Springs Capital Management 2023 Q2 filed Aug. 14, 2023
- Rock Springs Capital Management 2023 Q1 filed May 15, 2023
- Rock Springs Capital Management 2022 Q4 filed Feb. 14, 2023
- Rock Springs Capital Management 2022 Q3 filed Nov. 14, 2022
- Rock Springs Capital Management 2022 Q2 filed Aug. 15, 2022
- Rock Springs Capital Management 2022 Q1 filed May 16, 2022
- Rock Springs Capital Management 2021 Q4 filed Feb. 14, 2022
- Rock Springs Capital Management 2021 Q3 filed Nov. 15, 2021
- Rock Springs Capital Management 2021 Q2 filed Aug. 16, 2021
- Rock Springs Capital Management 2021 Q1 filed May 17, 2021
- Rock Springs Capital Management 2020 Q4 filed Feb. 16, 2021
- Rock Springs Capital Management 2020 Q3 filed Nov. 16, 2020
- Rock Springs Capital Management 2020 Q2 filed Aug. 14, 2020
- Rock Springs Capital Management 2020 Q1 filed May 15, 2020